Recent Updates
Recently added Catalysts
PEN Positive Sentiment

Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025

Tuesday, July 1, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Penumbra, Inc. has announced a conference call scheduled for July 29, 2025, to discuss its financial results for the second quarter of 2025. The call will take place after market close and will be accessible via phone and webcast. The company continues to lead in thrombectomy technology, focusing on improving patient outcomes.
Price reaction · baseline $250.68 (2025-07-01 close) · hit after-hours · clean, no other PEN news in the window
day 0 close · peak
-0.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Penumbra is hosting a conference call to discuss positive financial results.
  • The company is recognized as a leader in thrombectomy technology.
  • Innovative technologies are being developed for serious medical conditions.

Full Press Release Details

ALAMEDA, Calif.,July 1, 2025/PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2025 after market close onTuesday, July 29, 2025at4:30 PM Eastern Time. A press release with second quarter 2025 financial results will be issued after market close that day.

Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the "Investors" tab of the Company's website atwww.penumbrainc.com. The webcast will be available on the Company's website for at least two weeks following the completion of the call.

About PenumbraPenumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visitwww.penumbrainc.comand connect onInstagram,LinkedInandX.

Investor RelationsPenumbra, Inc.[email protected]

Frequently Asked Questions

When is Penumbra's Q2 2025 earnings call?

The earnings call is scheduled for July 29, 2025, at 4:30 PM Eastern Time.

How can I access the conference call?

You can access the call by dialing (888) 596-4144 or via the webcast on Penumbra's website.

What will be discussed during the earnings call?

The call will discuss Penumbra's financial results for the second quarter of 2025.

Where can I find the webcast after the call?

The webcast will be available on Penumbra's website for at least two weeks after the call.

ShareAdd on Google
Tags: PEN Viatris Investor Conferences Healthcare Penumbra thrombectomy financial results conference call Q2 2025
Last updated: Jul 1, 2025

Biotech snapshot

Cash runway
$659M liquidity · $0M/mo burn
Low dilution risk
Lead asset
Penumbra SystemPhase 2
Stroke →